New Break in the Fight Against Breast Cancer

Hybrid Pharmaceutical GenNxeix , the Genomics Biotech Engineering company, CEO Selene Flores gives us
New break in the fight against breast cancer is a science. From MD Anderson Houston TX,

New break in the fight against breast cancer, is a science term called autophagy. Autophagy is a biological process involving self-digestion of breast cellular material when breast cells are
deprived of nutrients or in stress. In most cases, Autophagy acts as a breast cell survival mechanism protecting breast cells from different types of stress. Autophagy has been shown to play roles in normal physiological processes including energy metabolism, organelle turnover, growth regulation, and aging. Impaired breast autophagy leads to cancer. Autophagy has also been implicated in the cellular response to anti-breast cancer therapies.

Identification and characterization of regulators of autophagy in patient samples, breast cancer cell line and mouse models is a area of research that GenNxHybrid GenNxeix scientist in Galveston Texas focus on.

GenNxeix functional genomics, and proteomics approaches to identify and characterize factors required for breast cell death and autophagy in the clinical breast cancer samples. GenNxeix pharmacodynamics and pharmacokinetic effect on autophagy in anti-cancer therapy. Alteration of autophagy in endocrine therapy, chemotherapy and/or irradiation therapy is the nature tested. Evidence suggests that autophagy acts as a tumour suppressor and should be stimulated to decrease the incidence of cancer in breast cells. Analysing the reletionship between tumour suppression and autophagy genes in breast cancer.

Autophagy is an evolutionarily conserved mechanism of cellular self-digestion in which proteins and organelles are degraded through delivery to lysosomes. GenNxeix notice defects in this process is implicated in breast cancer. To understand autophagy, we performed a functional screen in search of microRNAs (miRNAs), which regulate the autophagic flux in breast cancer cells. As a result GenNxeix Scientist identified the tumour suppressive miRNA, miR-101, as a potent inhibitor of basal, etoposide- and rapamycin-induced autophagy. GenNxeix Scienyidt uses transcriptome to identified three novel miR-101 targets, ”STMN1″, ”RAB5A” and ”ATG4D”. where siRNA-depletion of these genes phenocopied the effect of miR-101overexpression, to demonstrating the genes importance in autophagy regulation. Importantly, overexpression of ”STMN1″could partially rescue cells from miR-101-mediated inhibition of autophagy. As a Result miR-101-mediated inhibition of autophagy will sensitize breast cancer cells to 4-hydroxytamoxifen mediated cell death. This is a classic case where genomics is here to stay.